US 11,737,471 B2
Products having high efficacy omega-6/omega-3 balanced polyunsaturated fatty acids
Andrew Konopacki, Denmark, WI (US); and Michael Gurin, Glenview, IL (US)
Assigned to OMEGA FOODS, LLC, Two Rivers, WI (US)
Filed by OMEGA FOODS, LLC, Two Rivers, WI (US)
Filed on Jan. 19, 2023, as Appl. No. 18/156,907.
Application 18/156,907 is a continuation of application No. 17/860,066, filed on Jul. 7, 2022, granted, now 11,589,594.
Application 17/860,066 is a continuation of application No. 17/497,843, filed on Oct. 8, 2021, granted, now 11,490,630, issued on Nov. 8, 2022.
Application 17/497,843 is a continuation of application No. 17/175,457, filed on Feb. 12, 2021.
Application 17/175,457 is a continuation in part of application No. 16/877,093, filed on May 18, 2020, granted, now 10,918,114, issued on Feb. 16, 2021.
Application 16/877,093 is a continuation of application No. 14/871,541, filed on Sep. 30, 2015, granted, now 10,653,160, issued on May 19, 2020.
Application 14/871,541 is a continuation in part of application No. 14/288,090, filed on May 27, 2014, abandoned.
Application 14/288,090 is a continuation of application No. 14/055,619, filed on Oct. 16, 2013, granted, now 10,682,327, issued on Jun. 16, 2020.
Application 14/055,619 is a continuation of application No. PCT/US2012/033973, filed on Apr. 17, 2012.
Claims priority of provisional application 61/632,827, filed on Apr. 17, 2011.
Prior Publication US 2023/0148619 A1, May 18, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A23L 27/60 (2016.01); A23L 33/115 (2016.01); A23C 9/123 (2006.01); A21D 2/16 (2006.01); A23G 9/32 (2006.01); A23D 7/00 (2006.01); A23C 19/09 (2006.01); A23C 19/076 (2006.01); A23D 7/005 (2006.01); A61K 31/201 (2006.01); A23L 11/00 (2021.01); A61K 45/06 (2006.01); A61K 31/202 (2006.01); A23D 7/01 (2006.01); A23L 25/10 (2016.01); A23L 23/00 (2016.01); A23L 13/50 (2016.01); A23L 9/10 (2016.01); A23L 21/10 (2016.01); A61K 31/355 (2006.01); A23L 19/18 (2016.01); A23L 33/12 (2016.01); A23L 2/68 (2006.01); A23L 15/00 (2016.01); A23L 7/109 (2016.01); A23L 7/117 (2016.01); A23L 19/00 (2016.01); A23L 2/02 (2006.01)
CPC A23C 9/123 (2013.01) [A21D 2/16 (2013.01); A21D 2/165 (2013.01); A23C 19/076 (2013.01); A23C 19/0904 (2013.01); A23D 7/001 (2013.01); A23D 7/003 (2013.01); A23D 7/0053 (2013.01); A23D 7/011 (2013.01); A23G 9/327 (2013.01); A23L 2/02 (2013.01); A23L 2/68 (2013.01); A23L 7/109 (2016.08); A23L 7/117 (2016.08); A23L 9/10 (2016.08); A23L 11/05 (2016.08); A23L 13/50 (2016.08); A23L 15/20 (2016.08); A23L 19/09 (2016.08); A23L 19/18 (2016.08); A23L 21/10 (2016.08); A23L 23/00 (2016.08); A23L 25/10 (2016.08); A23L 27/60 (2016.08); A23L 27/63 (2016.08); A23L 33/115 (2016.08); A23L 33/12 (2016.08); A61K 31/201 (2013.01); A61K 31/202 (2013.01); A61K 31/355 (2013.01); A61K 45/06 (2013.01); A23V 2002/00 (2013.01)] 30 Claims
 
1. A nutritional composition comprising a combination of fatty acids, the combination of fatty acids comprising:
a. omega-3 fatty acids comprising
i. alpha-linolenic acid (ALA) and
ii. eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), or a combination of EPA and DHA;
b. omega-6 fatty acids comprising linoleic acid; and
c. omega-9 fatty acids comprising oleic acid;
wherein the composition comprises weight ratios of:
d. omega-6 fatty acids to omega-3 fatty acids ranging from about 0.01:1 to about 4:1, respectively;
e. omega-9 fatty acids to omega-3 fatty acids ranging from about 1:1 to about 4:1, respectively; and
f. ALA to EPA, DHA, or the combination of EPA and DHA ranging from about 0.01:1 to about 5:1, respectively.